Cantargia’s cancer drug plans face a moving target as new pancreatic cancer treatments take hold, which could make it harder for its lead program to stand out. At the same time, early signals in another blood cancer study and a broader platform could still unlock value—if the company can manage long development timelines and funding needs.Read more
Catalysts About Cantargia Cantargia is a clinical stage biotech company developing IL1RAP targeted antibody therapies for oncology and inflammatory or autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Cantargia Cantargia is a biotech company developing IL1RAP targeted antibodies for oncology and inflammatory or autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
